
-
FibroGen Inc NASDAQ:FGEN FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and idiopathic pulmonary fibrosis (IPF).
Location: 409 Illinois St, California, 94158-2509, US | Website: www.fibrogen.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
103.8M
Cash
140.7M
Avg Qtr Burn
-50.5M
Short % of Float
4.78%
Insider Ownership
0.85%
Institutional Own.
55.04%
Qtr Updated
06/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Roxadustat (ROW) Details Chronic kidney disease, Anemia | Approved Quarterly sales | |
Roxadustat Details Chemotherapy Induced Anemia | PDUFA Approval decision | |
Pamrevlumab Details Duchenne muscular dystrophy | Phase 3 Update | |
Roxadustat Details Myelodysplastic syndrome, Anemia | Phase 3 Update | |
FG-3246+ enzalutamide Details Cancer, Castration-resistant prostate cancer | Phase 2 Data readout | |
FG-3246 (ADC) Details Cancer, Castration-resistant prostate cancer | Phase 2 Initiation | |
FG-3165 Details Cancer, Solid tumor/s | Phase 1 Initiation | |
Pamrevlumab Details Cancer, Pancreatic cancer | Failed Discontinued | |
Pamrevlumab Details Pancreatic cancer, Cancer | Failed Discontinued | |
Pamrevlumab Details Idiopathic pulmonary fibrosis | Failed Discontinued | |
Pamrevlumab Details COVID-19, Infectious disease | Failed Discontinued | |
Roxadustat (U.S.) Details Anemia, Chronic kidney disease | Failed Discontinued |